You have full access to this article via your institution. Figure 1: A family with multiple GISTs and mutation of the KIT gene.

The tyrosine kinase inhibitor imatinib targets the human KIT receptor and the platelet-derived growth factor receptor-α. This drug exhibits impressive antitumor effects against GIST and has ...

IDRX-42 has demonstrated activity against all key primary and secondary KIT mutations, designed to improve outcomes for patients with GIST. Updated clinical data from StrateGIST 1, an ongoing ...

designed to address both primary and secondary KIT mutations in patients with GIST. Early data from the StrateGIST 1 Phase I/Ib trial demonstrated promising antitumor activity, with an objective ...

The first 2 criteria are associated with imatinib's efficacy in CML (BCR-ABL fusion), GIST (KIT or PDGFRA mutation), and HES (FIP1L1-PDGFRA fusion). The information we have for SCLC in regard to ...

IDRX-42 is a selective tyrosine kinase inhibitor (TKI) designed to treat gastrointestinal stromal tumours (GIST) by targeting all major KIT mutations, which are critical drivers of the disease.

and that GIST usually presents in the GI tract with 80% of cases driven by mutations in the KIT gene. IDRx's lead drug is designed to try and inhibit the mutations that drive the progression of ...

The focus of the presentation will be on the subgroup of patients who have received 100mg bezuclastinib for at least 48 weeks to highlight the symptomatic benefits of long-term use.

A live webcast can be accessed on the Investors & Media page of Cogent’s website at https://investors.cogentbio.com/events. A replay will be available approximately two hours after the completion of ...